This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Drug Therapy  • Adverse Effects  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;301(3):261-262.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New Orleans—Statin therapy using 80 mg of simvastatin daily may be on its last legs, some physicians suggest, because the drug is associated with increased risk of myopathy. In addition, when compared with the drug's efficacy at lower doses, high-dose simvastatin is minimally or no more effective in reducing low-density lipoprotein cholesterol (LDL-C) or decreasing risk of major vascular events.

The negative appraisal of high-dose simvastatin was prompted by new results from the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), presented at the Scientific Sessions of the American Heart Association held here in November.

In this randomized, double-blind, multicenter United Kingdom trial of 12 064 patients with a prior myocardial infarction, participants in 1 group were given 80 mg of simvastatin daily while those in the other group were given 20 mg of simvastatin daily. The researchers found that both statin regimens lowered . . . [Full Text of this Article]

WHY TAKE IT AT ALL?



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Does Simvastatin Cause More Myotoxicity Compared with Other Statins?
Backes et al.
The Annals of Pharmacotherapy 2009;43:2012-2020.
ABSTRACT | FULL TEXT